亞太地區(qū)腫瘤專家小組《德曲妥珠單抗相關不良反應的監(jiān)測和管理指南》解讀

Interpretation of "Guidelines for Monitoring and Management of Adverse Reactions Associated with Trastuzumab" issued by the Asia-Pacific Oncology Expert Group

TANG Xueqin，ZHENG Xueyan，WANG Qiaoling，LIU Li，LI Ben*Chongqing Health Center for Women and Children/Women and Children′s Hospital of Chongqing Medical University，Chongqing 401147 China*Corresponding Author LI Ben，E-mail：2019111189@stu.cqmu.edu.cn

Abstract This article interpreted "Guidelines for Monitoring and Management of Adverse Reactions Associated with Trastuzumab" issued by the Asia-Pacific Oncology Expert Group in August 2023.It aimed to provide practical suggestions for clinical medical staff to monitor and manage adverse events associated with trastuzumab.

Keywords breast cancer;trastuzumab deruxtecan;adverse reactions;human epidermal growth factor receptor 2;targeted therapy;nursing

摘要 對2023年8月亞太地區(qū)腫瘤專家小組發(fā)布的《德曲妥珠單抗相關不良反應的監(jiān)測和管理指南》進行解讀，旨在為臨床醫(yī)務人員監(jiān)測和管理德曲妥珠單抗相關不良事件提供實用建議。（剩余15738字）